References
Chu T, Kumagai Y, DiStefano EW, Cho AK (1996) Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 51:789–796
Colado MI, Williams JL, Green AR (1995) The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 115:1281–1289
de la Torre R, Farré M (2004) Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 25:505–508
de la Torre R, Farré M, Ortuno J, Mas M, Brenneisen R, Roset PN, Segura J, Cami J (2000) Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 49:104–109
de la Torre R, Farré M, Roset PN, Pizarro N, Abanandes S, Segura M, Segura J, Cami J (2004) Human pharmacology of MDMA, pharmacokinetics, metabolism and disposition. Ther Drug Monit 26:137–144
Easton N, Marsden CA (2006) Ecstasy: are animal data consistent between species and can they translate to humans? J Psychopharmacol 20:194–210
Esteban E, O’Shea E, Camarero J, Sanchez V, Green AR, Colado MI (2001) 3,4-methylenedioxymethamphetamine induces monoamine release but not toxicity when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology 154:251–260
Farré M, Abanades S, Roset PN, Peiro AM, Torrens M, O'Mathuna B, Segura M, de la Torre R (2007) Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther 323:954–962
Garrett ER, Seyda K, Marroum P (1991) High performance liquid chromatography assays of the illicit designer drug “ecstasy”, a modified amphetamine, with applications to stability, partitioning and plasma protein binding. Acta Pharm Nord 3:9–14
Goni-Allo B, Mathúna BÓ, Segura M, Puerta E, Lasheras B, de la Torre R, Aguirre N (2008) The relationship between core body temperature and 3,4-methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity. Psychopharmacology 197:263–278
Green AR, Mechan AO, Elliott JM, O’Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Revs 55:463–508
Green AR, Sanchez V, O’Shea E, Saadat KS, Elliott JM, Colado MI (2004) Effect of ambient temperature and a prior neurotoxic dose of 3, 4-methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated (‘binge’ ingestion) low dose of MDMA. Psychopharmacology 173:264–269
Green AR, Marsden CA, Fone KCF (2008) MDMA as a clinical tool: a note of caution. A response to Sessa and Nutt. J Psychopharmacol 22:929–931
Greene SL, Dargan PI, O’Connor N, Jones AL, Kerins M (2003) Multiple toxicity from 3,4-methylenedioxymethamphetamine (“ecstasy”). Am J Emerg Med 21:121–124
Hernandez-Lopez C, Farré M, Roset PN, Menoyo E, Pizarro N, Ortuno J, Torrens M, Cami J, de La Torre R (2002) 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther 300:236–244
Hiramatsu M, DiStefano E, Chang AS, Cho AK (1991) A pharmacokinetic analysis of 3,4-methylenedioxymethamphetamine effects on monoamine concentrations in brain dialysates. Eur J Pharmacol 204:135–140
Kolbrich EA Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA (2008) Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit 30:320–332
Mas M, Farré M, de la Torre R, Roset PN, Ortuno J, Segura J, Cami J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290:136–145
Mathúna BÓ, Farré M, Rastami-Hodjegan A, Yang J, Cuyas E, Torrens M, Pardo R, Abanades S, Maluf S, Tucker GT, de la Torre R (2008) The consequences of 3,4-methylenedioxymethamphetamine induced CYP 2D6 inhibition in humans. J Clin Psychopharmacol 28:523–531
McCann UD, Ricaurte GA (2001) Caveat emptor: editors beware. Neuropsychopharmacology 24:333–336
Mordenti J, Chappell W (1989) The use of interspecies scaling in toxicokinetics. In: Yacogi A, Kelly J, Batra V (eds) Toxicokinetics and new drug development. Pergamon, New York, pp 42–96
Morley-Fletcher S, Puopolo M, Gentili S, Gerara G, Macchia T, Laviola G (2004) Prenatal stress affects 3,4-methylenedioxymethamphetamine pharmacokinetics and drug induced motor alterations in adolescent female rats. Eur J Pharmacol 489:89–92
O’Shea E, Esteban B, Camarero J, Green AR, Colado MI (2001) Effect of GBR12909 and fluoxetine on the acute and long term changes induced by MDMA (“ecstasy”) on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology 40:65–71
Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD (2002) Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (“ecstasy”). Science 297:2260–2263
Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD (2003) Retraction. Science 301:1479
Sessa B, Nutt DJ (2007) MDMA, politics and medical research: have we thrown out the baby with the bathwater? J Psychopharmacol 21:787–791
Sessa B, Nutt DJ (2008) Reply to letter by Green Marsden and Fone (2007) about Sessa and Nutt’s editorial (MDMA: baby with the bathwater). J Psychopharmacol 22:457–458
Upreti VV, Eddington ND (2007) Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) in rat. J Pharmaceut Sci 97:1593–1605
Valtier S, Phelix CF, Cody JT (2007) Analysis of MDMA and its metabolites in urine and plasma following a neurotoxic dose of MDMA. J Analyt Toxicol 31:138–143
Yang J, Jamei M, Heydari A, Yeo KR, de la Torre R, Farré M, Tucker GT, Rostami-Hodjegan A (2006) Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol 20:842–849
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Green, A.R., Gabrielsson, J., Marsden, C.A. et al. MDMA: On the translation from rodent to human dosing. Psychopharmacology 204, 375–378 (2009). https://doi.org/10.1007/s00213-008-1453-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-008-1453-8